Detalhe da pesquisa
1.
Recent advances in Fragment-based strategies against tuberculosis.
Eur J Med Chem
; 258: 115569, 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37423127
2.
Rapid and Efficient Access to Novel Bio-Inspired 3-Dimensional Tricyclic SpiroLactams as Privileged Structures via Meyers' Lactamization.
Pharmaceuticals (Basel)
; 16(3)2023 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36986512
3.
Exploring the Antitubercular Activity of Anthranilic Acid Derivatives: From MabA (FabG1) Inhibition to Intrabacterial Acidification.
Pharmaceuticals (Basel)
; 16(3)2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36986435
4.
Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases.
J Med Chem
; 65(24): 16651-16664, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36473699
5.
On the Hunt for Next-Generation Antimicrobial Agents: An Online Symposium Organized Jointly by the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) on 9-10 December 2021.
Pharmaceuticals (Basel)
; 15(4)2022 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35455385
6.
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
Eur J Med Chem
; 200: 112440, 2020 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32505086